Zai Lab

Zai Lab is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States. It focuses on discovering, developing, and commercializing innovative products addressing medical conditions with significant unmet needs in oncology, immunology, neuroscience, and infectious disease. Founded in 2014 by Dr. Samantha Du, it describes itself as a partner of choice for leading global biopharmaceutical companies in China, combining in-licensed assets with strategic partnerships.

Zai Lab was founded in 2014 by Dr. Samantha Du. The company describes itself as purpose-built to become a leading global biopharma, combining scientific innovation, operational scale, and strong execution. It is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States, focused on discovering, developing, and commercializing innovative products that address medical conditions with significant unmet needs in oncology, immunology, neuroscience, and infectious disease. In China, it states it has earned a reputation as a partner of choice for leading global biopharmaceutical companies, leveraging its commercial infrastructure and clinical trial capabilities. Its business model combines in-licensed assets with strategic partnerships.

• 2014

  Zai Lab founded by Dr. Samantha Du.

• Zai Lab commercializes ZEJULA (niraparib) in mainland China, Hong Kong, and Macau.

• Zai Lab commercializes Tumor Treating Fields therapy, including OPTUNE GIO and OPTUNE LUA.

• Zocilurtatug pelitecan (formerly ZL-1310) enters clinical trials.

Innovation-driven global biopharma company dedicated to advancing breakthrough therapies from the lab to the lives of patients.

• ZEJULA (niraparib)

  An orally administered poly (ADP-ribose) polymerase (PARP) 1/2 inhibitor. Zai Lab currently sells ZEJULA in mainland China, Hong Kong and Macau as a first-line maintenance treatment for ovarian cancer and a maintenance treatment for platinum-sensitive relapsed ovarian cancer.

• OPTUNE GIO and OPTUNE LUA (Tumor Treating Fields)

  Tumor Treating Fields (TTFields) is a cancer therapy that uses electric fields tuned to selectively target and kill tumor cells via a variety of mechanisms, including disruption of mitosis, downregulation of DNA damage response, downstream enhancement of anti-tumor immunity, and interference of cell movement and migration. TTFields therapy is delivered through a portable medical device.

• 2020-07-07

  Zai Lab and Turning Point Therapeutics enter Repotrectinib licensing agreement[5]再鼎医药与Turning Point Therapeutics达成Repotrectinib授权许可协议tech.sina.com.cn

  Reported: 2020-07-08

  Zai Lab and Turning Point Therapeutics announced a licensing agreement under which Zai Lab will receive exclusive development and commercialization rights for Repotrectinib in Greater China. Turning Point will receive a $25 million upfront cash payment and may receive milestone payments, as well as royalties on annual net sales in the region.

• 2020-07-02

  Zai Lab licenses Greater China rights to repotrectinib[6]再鼎医药获得Repotrectinib大中华区授权finance.sina.com.cn

  Reported: 2020-07-07

  Zai Lab and Turning Point Therapeutics entered into a licensing agreement for investigational drug repotrectinib. Zai Lab obtained exclusive development and commercialization rights in Greater China, while Turning Point Therapeutics is to receive an upfront payment and potential milestone payments and royalties.

• 2020-04-08

  Zai Lab and Regeneron partner on REGN1979 in Greater China[7]再鼎医药与再生元就REGN1979达成区域合作prnasia.com

  Reported: 2020-04-08

  Zai Lab and Regeneron announced a strategic collaboration to develop and commercialize REGN1979 in mainland China, Hong Kong, Taiwan and Macau. Zai Lab received development and exclusive commercialization rights in the oncology field in those markets; Regeneron will manufacture and supply the product for the region.

1. 1Home - Zai Labzailaboratory.com
2. 2About Zai Lab - Zai Labzailaboratory.com
3. 3Products - Zai Labzailaboratory.com
4. 4Zai Lab Limitedwikidata.org
5. 5再鼎医药与Turning Point Therapeutics达成Repotrectinib授权许可协议tech.sina.com.cn
6. 6再鼎医药获得Repotrectinib大中华区授权finance.sina.com.cn
7. 7再鼎医药与再生元就REGN1979达成区域合作prnasia.com
8. 8Turning Point Therapeutics Reports Second-Quarter Financial Results, Provides Operational Updatesbiospace.com